menu search

: Madrigal Pharmaceuticals’ stock up 5% as company starts rolling submission for FDA approval of NASH treatment

Madrigal Pharmaceuticals Inc.’s stock MDGL rose 5% Friday after the company said it has started a rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of its resmetirom as a treatment for, nonalcoholic steatohepatitis, or NASH, with liver fibrosis. NASH is a more severe version of nonalcoholic fatty […] The post : Madrigal Pharmaceuticals’ stock up 5% as company starts rolling submission for FDA approval of NASH treatment appeared fir... Read More
Posted: Jun 30 2023, 16:28
Author Name: forextv
Views: 110667

Search within

Pages Search Results: